Inhibitor Therapeutics, Inc.
General ticker "INTI" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $12.0M (TTM average)
Inhibitor Therapeutics, Inc. follows the US Stock Market performance with the rate: 4.2%.
Estimated limits based on current volatility of 10.8%: low 0.05$, high 0.06$
Factors to consider:
- Company does not operate outside North America (retrieved using AI)
- Price in estimated range
- Earnings for 12 months up through Q4 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [0.07$, 0.22$]
- 2024-12-30 to 2025-12-30 estimated range: [0.06$, 0.17$]
Short-term INTI quotes
Long-term INTI plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $0.66MM | $3.40MM | $3.66MM |
| Operating Income | $-0.66MM | $-3.40MM | $-3.66MM |
| Non-Operating Income | $12.82MM | $0.38MM | $0.32MM |
| Interest Expense | $0.02MM | $0.00MM | $0.00MM |
| R&D Expense | $0.01MM | $1.38MM | $1.68MM |
| Income(Loss) | $12.16MM | $-3.03MM | $-3.34MM |
| Taxes | $0.06MM | $0.00MM | $0.00MM |
| Profit(Loss)* | $12.11MM | $-3.03MM | $-3.34MM |
| Stockholders Equity | $8.30MM | $5.28MM | $1.99MM |
| Assets | $11.98MM | $8.95MM | $5.69MM |
| Operating Cash Flow | $11.74MM | $-2.70MM | $-3.23MM |
| Capital expenditure | $0.00MM | $0.00MM | $0.00MM |
| Financing Cash Flow | $0.18MM | $-0.41MM | $0.00MM |
| Earnings Per Share** | $0.03 | $-0.02 | $-0.02 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.